United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $5.03, $1.69 better than the analyst estimate of $3.34. Revenue for the quarter came in at $461.9 million versus the consensus estimate of $420.02 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.